HHS Announces $147 Million to Support Ending the HIV Epidemic

April 27, 2023
The Health Resources and Services Administration announced on April 27 that it is awarding more than $147 million to help states and metropolitan areas with the highest levels of HIV transmission

On April 27, the Health Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human Services (HHS), announced via a press release that it has awarded more than $147 million to 49 recipients to advance the “Ending the HIV Epidemic in the U.S. (EHE)” initiative. The initiative is part of the Biden-Harris Administration’s efforts to decrease the number of new HIV infections in the United States by at least 90 percent by 2030.

The funding aims to assist states and metropolitan areas with the highest levels of HIV transmission get individuals with HIV access to essential care, support, and treatment. Additionally, the funding will support training and other resources for these areas.

The press release states that “Today’s awards include:

  • Nearly $139.1 million to metropolitan areas and states to implement strategies and interventions to provide medical and support services to reduce new HIV infections in the U.S.; and
  • $8 million to two non-profit organizations to provide training and other resources to recipients of EHE funds.”

Further, “The Ending the HIV Epidemic Initiative focuses on four key strategies:

  • Diagnose all people with HIV as early as possible.
  • Treat people with HIV rapidly and effectively to reach sustained viral suppression.
  • Prevent new HIV transmissions by using proven interventions.
  • Respond quickly to potential HIV outbreaks.”

The strategies expand on the Ryan White HIV/AIDS Program that supports medical care, medications, and support services for more than 576,000 people. Almost 90 percent of Ryan White clients that choose to receive care reach viral suppression. The national viral suppression average is 64.6 percent.

HHS Secretary Xavier Becerra was quoted in the release saying that “Ending the HIV epidemic requires us to reach people living with the virus where they are, and that’s exactly what this program allows us to do. Through this program and others, we will continue our work to destigmatize this deadly disease and ensure equitable access to testing and treatment.”

Sponsored Recommendations

Care Access Made Easy: A Guide to Digital Self Service

Embracing digital transformation in healthcare is crucial, and there is no one-size-fits-all strategy. Consider adopting a crawl, walk, run approach to digital projects, enabling...

Powering a Digital Front Door with a Comprehensive Provider Directory

Learn how Geisinger improved provider data accuracy, SEO, and patient acquisition with a comprehensive provider directory.

Data-driven, physician-focused approach to CDI improvement

Organizational profile Sisters of Charity of Leavenworth (SCL) Health* has been providing care since it originated in the 1600s in France as the Daughters of Charity. These religious...

Luminis Health improved quality and financial outcomes with advanced CDI technology and consulting from 3M

In the beginning, there were challengesBefore partnering with 3M Health Information Systems (HIS), Luminis Health’s clinical documentation integrity (CDI) program faced ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1